MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584403 | Name: Fluciclovine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluciclovine is a PET compound that is used in the detection of lesions.

Chemical Structure

Fluciclovine
Fluciclovine
CAS#222727-43-7

Theoretical Analysis

MedKoo Cat#: 584403

Name: Fluciclovine

CAS#: 222727-43-7

Chemical Formula: C5H8FNO2

Exact Mass: 133.0539

Molecular Weight: 133.12

Elemental Analysis: C, 45.11; H, 6.06; F, 14.27; N, 10.52; O, 24.04

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Fluciclovine; FACB
IUPAC/Chemical Name
Cyclobutanecarboxylic acid, 1-amino-3-fluoro-, trans-
InChi Key
NTEDWGYJNHZKQW-YUOXXFAHSA-N
InChi Code
InChI=1S/C5H8FNO2/c6-3-1-5(7,2-3)4(8)9/h3H,1-2,7H2,(H,8,9)/t3-,5+
SMILES Code
O=C([C@@]1(N)C[C@H](F)C1)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 133.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, Pettinato C, Martorana G, Fanti S. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT. Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849. PubMed PMID: 26053708. 2: Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, Chen Z, Goodman MM, Schuster DM. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18. PubMed PMID: 27091135; PubMed Central PMCID: PMC4970909. 3: Ono M, Oka S, Okudaira H, Nakanishi T, Mizokami A, Kobayashi M, Schuster DM, Goodman MM, Shirakami Y, Kawai K. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. Nucl Med Biol. 2015 Nov;42(11):887-92. doi: 10.1016/j.nucmedbio.2015.07.005. Epub 2015 Jul 15. PubMed PMID: 26278491. 4: Schreibmann E, Schuster DM, Rossi PJ, Shelton J, Cooper S, Jani AB. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial. Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):206-13. doi: 10.1016/j.ijrobp.2016.04.023. Epub 2016 Apr 30. PubMed PMID: 27511856; PubMed Central PMCID: PMC5645084. 5: Tade FI, Cohen MA, Styblo TM, Odewole OA, Holbrook AI, Newell MS, Savir-Baruch B, Li X, Goodman MM, Nye JA, Schuster DM. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study. J Nucl Med. 2016 Sep;57(9):1357-63. doi: 10.2967/jnumed.115.171389. Epub 2016 Apr 7. PubMed PMID: 27056619. 6: Ono M, Baden A, Okudaira H, Kobayashi M, Kawai K, Oka S, Yoshimura H. Assessment of Amino Acid/Drug Transporters for Renal Transport of [(18)F]Fluciclovine (anti-[(18)F]FACBC) in Vitro. Int J Mol Sci. 2016 Oct 14;17(10). pii: E1730. PubMed PMID: 27754421; PubMed Central PMCID: PMC5085761. 7: McConathy J. 18F-Fluciclovine (FACBC) and Its Potential Use for Breast Cancer Imaging. J Nucl Med. 2016 Sep;57(9):1329-30. doi: 10.2967/jnumed.116.175489. Epub 2016 May 19. PubMed PMID: 27199361. 8: Sörensen J, Owenius R, Lax M, Johansson S. Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):394-402. doi: 10.1007/s00259-012-2291-9. Epub 2012 Dec 4. PubMed PMID: 23208700. 9: McParland BJ, Wall A, Johansson S, Sørensen J. The clinical safety, biodistribution and internal radiation dosimetry of [¹⁸F]fluciclovine in healthy adult volunteers. Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1256-64. doi: 10.1007/s00259-013-2403-1. Epub 2013 Apr 24. PubMed PMID: 23613104. 10: Ulaner GA, Goldman DA, Gönen M, Pham H, Castillo R, Lyashchenko SK, Lewis JS, Dang C. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. J Nucl Med. 2016 Sep;57(9):1350-6. doi: 10.2967/jnumed.115.170456. Epub 2016 Mar 3. PubMed PMID: 26940766. 11: Kondo A, Ishii H, Aoki S, Suzuki M, Nagasawa H, Kubota K, Minamimoto R, Arakawa A, Tominaga M, Arai H. Phase IIa clinical study of [(18)F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors. Ann Nucl Med. 2016 Nov;30(9):608-618. Epub 2016 Jul 14. PubMed PMID: 27418267. 12: Schuster DM, Nanni C, Fanti S. Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. J Nucl Med. 2016 Oct;57(Suppl 3):61S-66S. Review. PubMed PMID: 27694174. 13: Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and (18)F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J Nucl Med. 2017 Dec 14. pii: jnumed.117.203257. doi: 10.2967/jnumed.117.203257. [Epub ahead of print] PubMed PMID: 29242404. 14: Jani AB, Schreibmann E, Rossi PJ, Shelton J, Godette K, Nieh P, Master VA, Kucuk O, Goodman M, Halkar R, Cooper S, Chen Z, Schuster DM. Impact of (18)F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial. J Nucl Med. 2017 Mar;58(3):412-418. doi: 10.2967/jnumed.116.176057. Epub 2016 Sep 8. PubMed PMID: 27609792; PubMed Central PMCID: PMC5331938. 15: Selnæs KM, Krüger-Stokke B, Elschot M, Willoch F, Størkersen Ø, Sandsmark E, Moestue SA, Tessem MB, Halvorsen D, Kjøbli E, Angelsen A, Langørgen S, Bertilsson H, Bathen TF. (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. Eur Radiol. 2018 Jan 2. doi: 10.1007/s00330-017-5213-1. [Epub ahead of print] PubMed PMID: 29294158. 16: Savir-Baruch B, Zanoni L, Schuster DM. Imaging of Prostate Cancer Using Fluciclovine. PET Clin. 2017 Apr;12(2):145-157. doi: 10.1016/j.cpet.2016.11.005. Epub 2017 Jan 23. Review. PubMed PMID: 28267449. 17: Oka S, Kanagawa M, Doi Y, Schuster DM, Goodman MM, Yoshimura H. PET Tracer (18)F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models. Theranostics. 2017 May 15;7(7):2048-2064. doi: 10.7150/thno.19883. eCollection 2017. PubMed PMID: 28656060; PubMed Central PMCID: PMC5485422. 18: Ulaner GA, Goldman DA, Corben A, Lyashchenko SK, Gönen M, Lewis JS, Dickler M. Prospective Clinical Trial of (18)F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers. J Nucl Med. 2017 Jul;58(7):1037-1042. doi: 10.2967/jnumed.116.183335. Epub 2016 Nov 17. PubMed PMID: 27856630. 19: Schuster DM, Nanni C, Fanti S. PET Tracers Beyond FDG in Prostate Cancer. Semin Nucl Med. 2016 Nov;46(6):507-521. doi: 10.1053/j.semnuclmed.2016.07.005. Epub 2016 Sep 7. Review. PubMed PMID: 27825431; PubMed Central PMCID: PMC5117950. 20: Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol. 2016 Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2. Review. PubMed PMID: 26850970.

View History

Fluciclatide

Fluciclatide